trazodone has been researched along with Drug-Related Side Effects and Adverse Reactions in 8 studies
Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.
Drug-Related Side Effects and Adverse Reactions: Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the study was to evaluate the efficacy, tolerability, and safety of once-a day trazodone tablets (Trittico Prolong® 300 mg) in patients with moderate to severe depression in routine clinical practice." | 7.88 | Once-a-Day Trazodone in the Treatment of Depression in Routine Clinical Practice. ( Češková, E; Kellnerová, R; Šedová, M; Starobová, O, 2018) |
| "The aim of the study was to evaluate the efficacy, tolerability, and safety of once-a day trazodone tablets (Trittico Prolong® 300 mg) in patients with moderate to severe depression in routine clinical practice." | 3.88 | Once-a-Day Trazodone in the Treatment of Depression in Routine Clinical Practice. ( Češková, E; Kellnerová, R; Šedová, M; Starobová, O, 2018) |
| "Trazodone was associated with lower side effects and with augmentation treatments." | 1.91 | Characterisation of medication side effects in patients with mostly resistant depression in a real-world setting. ( De Ronchi, D; Fabbri, C; Ferentinos, P; Kasper, S; Mendlewicz, J; Montgomery, S; Panariello, F; Rujescu, D; Serretti, A; Souery, D; Zohar, J, 2023) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Chen, M | 1 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 2 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Panariello, F | 1 |
| Kasper, S | 1 |
| Zohar, J | 1 |
| Souery, D | 1 |
| Montgomery, S | 1 |
| Ferentinos, P | 1 |
| Rujescu, D | 1 |
| Mendlewicz, J | 1 |
| De Ronchi, D | 1 |
| Serretti, A | 1 |
| Fabbri, C | 1 |
| Češková, E | 1 |
| Šedová, M | 1 |
| Kellnerová, R | 1 |
| Starobová, O | 1 |
| Birur, B | 1 |
| Fargason, RE | 1 |
| Moore, N | 1 |
| Kast, RE | 1 |
8 other studies available for trazodone and Drug-Related Side Effects and Adverse Reactions
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Characterisation of medication side effects in patients with mostly resistant depression in a real-world setting.
Topics: Anxiety Disorders; Depression; Depressive Disorder, Treatment-Resistant; Drug-Related Side Effects a | 2023 |
Once-a-Day Trazodone in the Treatment of Depression in Routine Clinical Practice.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Depression; Drug Administration Schedule; Dru | 2018 |
Delayed-onset of psychopharmacologically induced priapism: A cautionary case report.
Topics: Adult; Antipsychotic Agents; Drug Interactions; Drug Substitution; Drug-Related Side Effects and Adv | 2015 |
Trazodone generates m-CPP: in 2008 risks from m-CPP might outweigh benefits of trazodone.
Topics: Animals; Antidepressive Agents, Second-Generation; Anxiety; Biotransformation; Brain; Dose-Response | 2009 |